Evidence map›Paper›PMID 36499340›Full record

ReviewInternational journal of molecular sciences2022

B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy.

Xin Chen, Jie Li, Yue Chen, Ziting Que, Jiawei Du, Jianqiong Zhang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xin ChenDepartment of Microbiology and Immunology, Medical School, Southeast University, Nanjing 210009, China.
Jie LiDepartment of Microbiology and Immunology, Medical School, Southeast University, Nanjing 210009, China.
Yue ChenDepartment of Microbiology and Immunology, Medical School, Southeast University, Nanjing 210009, China.
Ziting QueDepartment of Microbiology and Immunology, Medical School, Southeast University, Nanjing 210009, China.
Jiawei DuJiangsu Key Laboratory of Molecular Imaging and Function Imaging, Medical School, Southeast University, Nanjing 210009, China.
Jianqiong ZhangDepartment of Microbiology and Immunology, Medical School, Southeast University, Nanjing 210009, China.
Southeast University · CN

Funding

National Natural Science Foundation of China NSFC 92059202Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX20_0146
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a five-year survival rate of approximately 5-10%. The immune checkpoint blockade represented by PD-1/PD-L1 inhibitors has been effective in a variety of solid tumors but has had little clinical response in pancreatic cancer patients. The unique suppressive immune microenvironment is the primary reason for this outcome, and it is essential to identify key targets to remodel the immune microenvironment. Some B7 family immune checkpoints, particularly PD-L1, PD-L2, B7-H3, B7-H4, VISTA and HHLA2, have been identified as playing a significant role in the control of tumor immune responses. This paper provides a comprehensive overview of the recent research progress of some members of the B7 family in pancreatic cancer, which revealed that they can be involved in tumor progression through immune-dependent and non-immune-dependent pathways, highlighting the mechanisms of their involvement in tumor immune escape and assessing the prospects of their clinical application. Targeting B7 family immune checkpoints is expected to result in novel immunotherapeutic treatments for patients with pancreatic cancer.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsB7-H1 AntigenHumansImmunoglobulinsImmunotherapyTumor MicroenvironmentB7-H1 AntigenHHLA2 protein, humanImmunoglobulinsB7 familycancer immunotherapyimmune checkpointnovel targeted immunotherapiespancreatic ductal adenocarcinoma

Identifiers

PMID36499340
PMCPMC9740860
OpenAlexW4311002412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.